University of Chicago
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Inclusion Criteria: * Persons receiving ongoing oncology care at the University of Chicago Medical Center for whom near-future pain opioid pain medication therapy is anticipated * Subjects must be at least 18 years of age. Exclusion Criteria: * Subjects taking an opioid at the time of enrollment, or within the past 30 days * Subjects who are currently undergoing palliative radiation * Subjects who have undergone, or are being actively considered for, bone marrow, liver or kidney transplantation. * Subjects with a history of or active blood cancer (e.g., leukemia). * Chronic kidney disease,…
These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
Arctuva estimate
Verify or correct the compensation shown for this listing.